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Abstract
Grutters et al show that economic assessments can inform the development of new health technologies at an 
early stage. This is an important contribution to health services and policy research, which implies a “shift away” 
from the more traditional forms of academic health economic modeling. Because transforming established 
disciplinary traditions is both valuable and demanding, we invite scholars to further the discussion on how the 
value of health innovations should be appraised in view of today’s societal challenges.
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By showing that it is possible to inform at an early stage the development of new health technologies with cost-effectiveness analyses, the study of Grutters et al1 
brings an important contribution to health services and policy 
research. According to the authors, one implication of their 
study emphasizes “a shift away from traditional use of health 
economic modeling” towards an analysis of “what is needed 
for a technology to provide most value for money.”1 In this 
commentary, we argue that what makes health innovations 
valuable in the context of 21st century societal challenges lies 
with dimensions that are broader than their costs and effects. 
We thus invite scholars to further the discussion on ways to 
transform our scholarly traditions.
Informing Decisions That Are Made “Upstream” About 
Health Innovations
Aligned with previous work on the use of economic modeling 
in health technology assessment (HTA),2 one important key 
message from the study of Grutters et al1 is to recognize that 
health economists can provide innovators with precious 
insights at an early stage in the development of a new 
screening test, diagnostic or treatment. According to their 
study, such insights can help to redefine an innovation’s value 
proposition when it is still possible to do so, to inform how 
further development may enhance its cost-effectiveness or to 
reposition an innovation within the care pathway. Interestingly, 
up to 69% of the 32 early assessments these authors performed 
have led to the latter type of recommendations. It may reflect 
the knowledge gap that innovators sometimes face when they 
lack direct access to academic expertise in health services 
and policy research. Though innovators and their investors 
are familiar with market analyses, demographic projections 
and epidemiologic trends,3 they are less frequently exposed 
to findings regarding the comparative effectiveness of health 
interventions, the varying burdens of disease experienced 
by different patient sub-groups and current inefficiencies in 
care provision and their opportunity costs. These are precious 
insights that “untraditional” academic health economic 
research can provide.
We particularly appreciated the examples described by the 
authors since they illustrate very well how some of the key 
limitations of an innovation can be identified “upstream,” ie, 
before it makes its way into routine clinical practice.4 Stressing 
that an innovation’s cost-effectiveness is “always dependent 
on its context,” the authors recognize that “health economic 
modeling is only one tool to understand this context, and 
interviews with stakeholders to build and validate the model 
are essential.”1 In our view, it would prove equally important to 
consider the relationship between the various settings where 
an innovation may be used (academic centres, primary care 
centres, the patient’s home) and the level of skills required to 
use it appropriately since the latter influences overall costs 
(eg, training, user support, infrastructure, maintenance, etc).4
Can Cost-Effectiveness Analyses Help Innovators Develop 
More Valuable Innovations?
We were however puzzled by the authors’ “unproblematized” 
use of the Dutch cost-effectiveness threshold of €20 000 to 
€80 000 per quality adjusted life year. If the aim is to shift 
away from scholarly traditions, questioning whether health 
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economists should continue to use such thresholds seems 
warranted. The origin of the US$50 000 per quality adjusted 
life year benchmark that “first emerged in 1992 and became 
widely used after 1996” was loosely linked to the cost-
effectiveness literature from the 1980s on kidney dialysis for 
end-stage renal disease, but the history of this practice and its 
implications for the sustainability of health systems are not 
always fully addressed.5 Without an explicit cost-effectiveness 
threshold, “there exists greater potential for decision-makers 
to feel increased pressure to approve or reject certain drugs 
due to the zeitgeist of the current political landscape.”6 Yet, 
if thresholds persist to raise as more expansive treatments 
continue to emerge in rich countries, they may not fulfill 
any meaningful purpose. As Griffiths et al7 underscore, 
“thresholds set so high that nearly all possible interventions 
are considered ‘cost‐effective’ cannot contribute effectively 
to priority setting.” Furthermore, critics consider that such 
thresholds “are unable to capture all the important values for 
society, particularly ethical implications, distributive justice, 
and other social preferences.”8
We also wonder whether such thresholds can guide 
innovators towards the development of the innovations 
contemporary health systems need. In other words, is it 
sufficient to assess costs and effects at an early stage and 
then seek to optimize the ratio? In their study, Grutters et al1 
conclude that all of the 30 innovations they examined could 
potentially become cost-effective. This indirectly implies 
that they could all compete for the same limited healthcare 
resources. This is an issue the authors do not fully address, 
although they recognize the misalignment between a 
potentially cost-effective innovation and the administrative 
mechanism enabling its reimbursement, acquisition or use. 
Such barriers are well-known to health system observers, 
but they are not under the control of those who develop 
innovations. One may thus wonder whether early economic 
modelling may, in practice, guide the development of more 
valuable innovations. 
For Grutters et al,1 other considerations such as “risks, 
competing upcoming innovations and logistical issues” may 
limit the commercial viability of an innovation even if it is 
potentially cost-effective. In view of the rising Research & 
Development costs and the high failure rate of emerging 
technology-based companies,9 we would argue in favor of 
making much more explicit these other considerations. 
Improving the efficiency of Research & Development 
processes in healthcare is a matter of high societal importance, 
one that goes beyond health system governance and raises 
questions about the kinds of health innovation our systems of 
innovation should deliver.
What Makes Health Innovations Valuable in View of 
Current Societal Challenges?
Rather than seeking to estimate the “exact cost-effectiveness 
of a technology,” Grutters et al1 suggest that health economists 
should further explore “what is needed for a technology to 
provide most value for money.” Perhaps “value for money” is a 
term that deserves further definition for such an exploration to 
prove fruitful in the long run. In their scoping review on early 
HTA models, Fasterholdt et al3 identified 24 models, which 
they considered “immature” as they lacked clarity about what 
is meant by “early” and “value.” In our view, the term “early” 
should be defined in relation to the transformational impact 
an evaluation may have over an innovation, while recognising 
that the time and efforts needed to develop a medical device 
differ considerably from those needed to develop a drug. 
An assessment would be called early when it can be used to 
redefine an innovation’s initial value proposition and/or when 
it can make its position within the care pathway more valuable 
for health systems. In other words, an assessment arrives “late” 
when it can no longer transform what the innovation can 
achieve in practice. With respect to what is meant by “value,” 
since three quarters of the 24 early HTA models Fasterholdt 
et al3 identified only assess costs and effectiveness, efforts 
to develop early assessment frameworks should also clarify 
when a focus on cost-effectiveness should be maintained and 
when broader upstream considerations should be considered 
as well.
More fundamentally, the “shift away” Grutters et al1 evoke 
should start by asking, ‘what makes health innovations 
valuable in view of today’s societal challenges?’ To address 
the United Nation Sustainable Development Goals or the 
Horizon 2020 societal challenges, recent work around 
socially responsible innovation in health bring to the fore 
additional value dimensions such as the sustainability of 
health systems, the reduction of health inequalities and the 
protection of the environment.10-12 Our own efforts to define 
a framework for Responsible Innovation in Health builds on 
the interdisciplinary policy-oriented field of research called 
Responsible Research and Innovation, which recognizes that 
today’s societal challenges should steer the development of 
the next generation of innovations.10 
The Responsible Innovation in Health framework posits 
that health innovations should not only prove effective and 
safe, but should also address the needs and challenges of 
health systems in an equitable and sustainable way. One of 
its five value domains brings to health economists’ attention 
the importance of developing high-performing products 
as well as affordable ones, which is best captured under 
the concept of “frugality.” It draws attention to the extent 
to which an innovation is designed to deliver greater value 
to more people by using fewer resources such as capital, 
materials, energy and labour time. Frugality may increase the 
economic value of a health innovation: (1) by increasing its 
affordability, which may result from optimized innovation 
production processes and/or lower maintenance needs; (2) 
by focusing on core functionalities and ease of use in order 
to meet the requirements of a larger number of users; and 
(3) by optimizing its performance level in order to maximize 
the fit between its characteristics and its context of use (eg, 
robustness if used in difficult climatic conditions, economies 
of scale if used in large centers, etc).13 
Empirical research suggests that frugal innovations are 
better known in low-resource countries. For instance, a 
non-profit manufacturing company in India developed 
intraocular lens and ophthalmic drugs to treat non-
communicable eye diseases (cataract, glaucoma, age-related 
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macular degeneration, diabetic retinopathy) in marginalized 
people.14 Nonetheless, the concept of frugality can be applied 
anywhere to design low-cost, high quality solutions, including 
sophisticated technologies (eg, gene circuits on paper for 
identifying pathogens, robots made of cellphone parts).15 
Prime et al16 examined the Arbutus Drill Cover System, which 
is a reusable double-layered surgical-grade cover that fully 
encloses a hardware drill and transforms it into a surgical 
grade drill. Developed by a team of Canadian and Ugandan 
engineers, surgeons, nurses, reprocessing staff and managers, 
it costs around £1500. If the Arbutus Drill Cover System were 
to be adopted in the British National Health System (replacing 
approximately 5000 drills at £23 000 each), it would generate a 
saving of 94%.16 
Overall, in view of today’s societal challenges, seeking to 
transform disciplinary traditions may prove both valuable and 
necessary. As such, Grutters et al1 should be lauded. Because 
scholarly traditions are resistant to change, we invite scholars 
to further the discussion on ways to provide innovators with 
useful insights at an early stage.
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